申请人:E. R. Squibb & Sons, Inc.
公开号:US05827868A1
公开(公告)日:1998-10-27
Thromboxane receptor antagonist activity is exhibited by compounds of the formula ##STR1## wherein: V is --(CH.sub.2).sub.m --, --O--, or ##STR2## but if V is --O--or ##STR3## R.sup.3 and R.sup.4 must complete an aromatic ring; W is --(CH.sub.2).sub.2 --, --CH.dbd.CH-- or phenylene; X is a single bond, --CH.dbd.CH--, --(CH.sub.2).sub.n --, or --O--(CH.sub.2).sub.n --; or X is branched alkylene or --O--branched alkylene wherein W is linked to Y through a chain n carbon atoms long; Y is --CO.sub.2 H, --CO.sub.2 alkyl, --CO.sub.2 alkali metal, --CH.sub.2 OH, --CONHSO.sub.2 R.sup.5, --CONHR.sup.6, or --CH.sub.2 -5-tetrazolyl; Z is O or NH; R.sup.3 and R.sup.4 are each independently hydrogen or alkyl or R.sup.3 and R.sup.4 together complete a ring optionally substituted through a ring carbon with a halo, lower alkyl, phenyl, halo (lower alkyl), halophenyl, oxo or hydroxyl group; and the remaining symbols are as defined in the specification.
血栓素受体拮抗活性由以下式的化合物展示:##STR1## 其中:V为--(CH.sub.2).sub.m --,--O--,或##STR2## 但如果V为--O--或##STR3##,则R.sup.3和R.sup.4必须形成一个芳香环;W为--(CH.sub.2).sub.2 --,--CH.dbd.CH--或苯基;X为单键,--CH.dbd.CH--,--(CH.sub.2).sub.n --,或--O--(CH.sub.2).sub.n --;或X为支链烷基或--O--支链烷基,其中W通过一个含有n个碳原子的链连接到Y;Y为--CO.sub.2 H,--CO.sub.2 烷基,--CO.sub.2 碱金属,--CH.sub.2 OH,--CONHSO.sub.2 R.sup.5,--CONHR.sup.6,或--CH.sub.2 -5-四唑基;Z为O或NH;R.sup.3和R.sup.4分别独立地为氢或烷基,或R.sup.3和R.sup.4一起形成一个环,该环可以通过一个含有卤素、低烷基、苯基、卤代(低烷基)、卤代苯基、氧代或羟基基团的环碳原子进行选择性取代;其余符号如规范中定义。